NRAS and Carcinoma, Lewis Lung: Indeed, treating either KRASG12C-expressing MEFs or the established Lewis lung carcinoma cell line (3LL) - in which NRAS was knocked out (deltaNRAS86) leaving them only with an activating point mutation in KRASG12C [26] - with the KRASG12C inhibitor AMG510 sensitized these cells to ferroptosis (Supplementary Fig. 1d, e).